Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepotastine besilate - Mitsubishi Tanabe Pharma Corporation

Drug Profile

Bepotastine besilate - Mitsubishi Tanabe Pharma Corporation

Alternative Names: Bepotastine; Bepreve; Betotastine; Betotastine besilate; Talion; TAU-284

Latest Information Update: 19 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ube Industries
  • Developer ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Ube Industries
  • Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Butyric acids; Chlorobenzenes; Eye disorder therapies; Piperidines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Pruritus; Urticaria
  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 10 Feb 2020 Dong-A ST completes a phase I trial in Healthy volunteers in South Korea (NCT03932435)
  • 30 Dec 2019 Registered for Allergic rhinitis (In children, In adolescents, In adults) in Thailand (PO)
  • 30 Dec 2019 Registered for Pruritus (In children, In adolescents, In adults) in Thailand (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top